Global BioAccess Fund

Global BioAccess Fund is a New York-based venture capital firm that invests in early-stage companies developing novel therapeutics and devices to address serious unmet medical needs in oncology, immunology, rare diseases, central nervous system disorders, and cardiology. The firm focuses on providing capital to support Investigational New Drug (IND) submissions and clinical trials, aiming to accelerate the development of innovative medical treatments.

The fund's investment strategy centers on transformative technologies that can significantly impact patient care in its target therapeutic areas. By partnering with forward-thinking companies, Global BioAccess Fund seeks to advance the next generation of medicines. The firm has a history of co-investing with other prominent investors, such as Pfizer, Amgen, LG Corp., Lotte Holdings CVC, and Finchley H.V., to support its portfolio companies.

Since its inception in 2021, Global BioAccess Fund has made several investments, including in companies like Nuvig Therapeutics, ShiraTronics, and Acesion Pharma. These investments reflect the firm's commitment to supporting innovative life sciences ventures that address critical health challenges. The fund's approach combines financial backing with strategic guidance to help portfolio companies navigate the complex landscape of medical product development.